View Item 

Show simple item record

CRT-D Therapy in Heart Failure: How Much Do NYHA Class IV Patients Benefit?

dc.contributor.authorLehmann, Michael E.en_US
dc.contributor.authorAaronson, Keith D.en_US
dc.date.accessioned2010-06-01T18:27:06Z
dc.date.available2010-06-01T18:27:06Z
dc.date.issued2006-05en_US
dc.identifier.citationLEHMANN, MICHAEL H.; AARONSON, KEITH D. (2006). "CRT-D Therapy in Heart Failure: How Much Do NYHA Class IV Patients Benefit?." Journal of Cardiovascular Electrophysiology 17(5): 491-494. <http://hdl.handle.net/2027.42/71659>en_US
dc.identifier.issn1045-3873en_US
dc.identifier.issn1540-8167en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/71659
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=16684020&dopt=citationen_US
dc.format.extent126136 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Publishing Incen_US
dc.rights2006 by Futura Publishing Company, Inc.en_US
dc.titleCRT-D Therapy in Heart Failure: How Much Do NYHA Class IV Patients Benefit?en_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelInternal Medicine and Specialtiesen_US
dc.subject.hlbsecondlevelPhysiologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationum* Department of Internal Medicine/Division of Cardiovascular Disease, University of Michigan School of Medicine, Ann Arbor, Michigan, USAen_US
dc.identifier.pmid16684020en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/71659/1/j.1540-8167.2006.00478.x.pdf
dc.identifier.doi10.1111/j.1540-8167.2006.00478.xen_US
dc.identifier.sourceJournal of Cardiovascular Electrophysiologyen_US
dc.identifier.citedreference1.  DEFIBRILAT Study Group: Actuarial risk of sudden death while awaiting cardiac transplantation in patients with atherosclerotic heart disease. Am J Cardiol 1991; 68: 545 - 546.en_US
dc.identifier.citedreference2.  MERIT-HF Study Group: Effect of Metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). Lancet 1999; 353: 2001 - 2007.en_US
dc.identifier.citedreference3.  The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators: A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997; 337: 1576 - 1583.en_US
dc.identifier.citedreferenceMoss AJ, Hall J, Cannom DS, Daubert JP, Higgins SL, Klein H, Levine JH, Saksena S, Waldo AL, Wilbe r D, Brown MW, Heo M, for the Multicenter Automatic Defibrillator Implantation Trial Investigators: Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 1996; 326: 1933 - 1940.en_US
dc.identifier.citedreferenceCurtis AB, Cannom DS, Bigger T, DiMarco JP, Estes NAM, Steinman RC, Parides MK: Baseline characteristics of patients in the coronary artery bypass graft (CABG) patch trial. Am Heart J 1997; 133: 787 - 798.en_US
dc.identifier.citedreferenceBuxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G, for the Multicenter Unsustained Tachycardia Trail Investigators: A randomized study of the prevention of sudden death in patients with coronary artery disease. N Engl J Med 1999; 341: 1882 - 1890.en_US
dc.identifier.citedreferenceMoss AJ, Zareba W, Hall J, Klein H, Wilber DJ, Cannom DS, Daubert JP, Higgins SL, Brown MW, Andrews ML, for the Multicenter Automatic Defibrillator Implantation Trial II Investigators: Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346: 877 - 883.en_US
dc.identifier.citedreferenceKadish A, Dyer A, Daubert JP, Quigg R, Estes M, Anderson KP, Calkins H, Hoch D, Goldberger J, Shalaby A, Sanders WE, Schaechter A, Levine JH, for the Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators: Prophylactic defibrillator implantation in patients with non-ischemic dilated cardiomyopathy. N Engl J Med 2004; 350: 2151 - 2158.en_US
dc.identifier.citedreferenceBardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, Troutman C, Anderson J, Johnson G, McNulty SE, Clapp-Channing N, Davidson-Ray LK, Fraulo ES, Fishbein DP, Luceri RM, Ip HJ, for the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators: Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352: 225 - 237.en_US
dc.identifier.citedreferenceAbraham WT, Fisher WG, Smith AL, Delurgio DB, Leon AR, Loh E, Kocovic DZ, Packer M, Clavell AL, Hayes DL, Ellestad M, Messenger J, for the MIRACLE Study Group: Cardiac resynchronization in chronic heart failure. N Engl J Med 2002; 346: 1845 - 1853.en_US
dc.identifier.citedreferenceLinde C, Leclercq C, Rex S, Garrigue S, Lavergne T, Cazeau S, McKenna W, Fitzgerald M, Deharo JC, Alonso C, Walker S, Braunschweig F, Bailleul C, Daubert JC, on behalf of the MUltisite STimulation In Cardiomyopathy (MUSTIC) Study Group: Long-term benefits of biventricular pacing in congestive heart failure: Results from the MUltisite STimulation In Cardiomyopathy (MUSTIC) Study. J Am Coll Cardiol 2002; 40: 111 - 118.en_US
dc.identifier.citedreferenceYoung JB, Abraham WT, Smith AL, Leon AR, Lieberman R, Wilkoff B, Canby RC, Schroeder JS, Liem LB, Hall S, Wheelan K, for the Multicenter InSync ICD Randomized Clinical Evaluation (MIRACLE ICD) Trial Investigators: Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: The MIRACLE ICD trial. JAMA 2003; 289: 2685 - 2694.en_US
dc.identifier.citedreferenceHiggins SL, Hummel JD, Niazi IK, Giudici MC, Worley SJ, Saxon LA, Boehmer JP, Higginbotham MB, De Marco T, Foster E, Yong PG: Cardiac resynchronization therapy for the treatment of heart failure in patients with intraventricular tachyarrhythmias. J Am Coll Cardiol 2003; 42: 1454 - 1459.en_US
dc.identifier.citedreferenceBristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, Carson P, DiCarlo L, DeMets D, White BG, DeVries DW, Feldman AM, for the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators: Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004; 350: 2140 - 2150.en_US
dc.identifier.citedreferenceCleland JGF, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi L, for the Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators: The effect of cardiac resynchronization on morbidity in heart failure. N Engl J Med 2005; 352: 1539 - 1549.en_US
dc.identifier.citedreferenceDesai AD, Burke MC, Hong TE, Kim S, Salem Y, Yong PG, Knight BP: Predictors of appropriate defibrillator therapy among patients with an implantable defibrillator that delivers cardiac resynchronization therapy. J Cardiovasc Electrophysiol 2006; doi:en_US
dc.identifier.citedreferenceUretsky BF, Sheahan RG: Primary prevention of sudden cardiac death in heart failure: Will the solution be shocking? J Am Coll Cardiol 1997; 30: 1589 - 1597.en_US
dc.identifier.citedreferenceWathen MS, Degroot PJ, Sweeney MO, Stark AJ, Otterness MF, Adkisson WO, Canby RC, Khalighi K, Machado C, Rubenstein DS, Volosin KJ, for the PainFREE Rx II Investigators: Prospective randomized multicenter trial of empirical antitachycardia pacing versus shocks for spontaneous implantable cardioverter-defibrillators: Pacing fast ventricular tachycardia reduces shock therapies (PainFREE Rx II) trial results. Circulation 2004; 110: 2591 - 2596.en_US
dc.identifier.citedreferenceEllenbogen KA, Levine JH, Berger RD, Daubert JP, Winters SL, Greenstein E, Shalaby A, Schaechter A, Subacius H, Kadish A, for the Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators: Are implantable cardioverter defibrillator shocks a surrogate for sudden cardiac death in patients with nonischemic cardiomyopathy? Circulation 2006; 113: 776 - 782.en_US
dc.identifier.citedreferenceSaxon LA, Wiener I, DeLurgio DB, Natterson PD, Laks H, Drinkwater DC, Stevenson WG: Implantable defibrillators for high-risk patients with heart failure who are awaiting cardiac transplantation. Am Heart J 1995; 130: 501 - 506.en_US
dc.identifier.citedreferenceSaba S, Atiga WL, Barrington W, Ganz LI, Kormos RL, MacGowan GA, Mathier MA, McNamara DM, Obioha-Ngwu O, Murali S: Selected patients listed for cardiac transplantation may benefit from defibrillator implantation regardless of an established indication. J Heart Lung Transplant 2003; 22: 411 - 418.en_US
dc.identifier.citedreferenceSandner SE, Wieselthaler G, Zuckermann A, Taghavi S, Schmidinger H, Pacher R, Ploner M, Laufer G, Wolner E, Grimm M: Survival benefit of the implantable cardioverter-defibrillator in patients on the waiting list for cardiac transplantation. Circulation 2001; 104 ( Suppl I ): I171 - I176.en_US
dc.identifier.citedreferenceSingh SN, Fletcher RD, Fisher SG, Singh BN, Lewis HD, Deedwania PC, Massie BM, Colling C, Lazzeri D, for the Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure: Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med 1995; 333: 77 - 82.en_US
dc.identifier.citedreferenceIuliano S, Fisher SG, Karasik PE, Fletcher RD, Singh SN, for the Department of Veterans Affairs Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure: QRS duration and mortality in patients with congestive heart failure. Am Heart J 2002; 143: 1085 - 1091.en_US
dc.identifier.citedreferenceLecoq G, Leclercq C, Leray E, Crocq C, Alonso C, de Place C, Mabo P, Daubert C: Clinical and electrocardiographic predictors of a positive response to cardiac resynchronization therapy in advanced heart failure. Eur Heart J 2005; 26: 1094 - 1100.en_US
dc.identifier.citedreferenceMolhoek SG, Bax JJ, Bleeker GB, Holman ER, Van Erven L, Bootsma M, Boersma E, Steendijk P, Van Der Wall EE, Schalij MJ: Long-term follow-up of cardiac resynchronization therapy in patients with end-stage heart failure. J Cardiovasc Electrophysiol 2005; 16: 701 - 707.en_US
dc.identifier.citedreferenceHiggins SL, Yong P, Scheck D, McDaniel M, Bollinger F, Vadecha M, Desai S, Meyer DB, for the Ventak CHF Investigators: Biventricular pacing diminishes the need for implantable cardioverter defibrillator therapy. J Am Coll Cardiol 2000; 36: 824 - 827.en_US
dc.identifier.citedreferenceArya A, Haghjoo M, Dehghani MR, Alasti M, Alizadeh H, Kazemi B, Sadr-Ameli MA: Effect of cardiac resynchronization therapy on the incidence of ventricular arrhythmias in patients with an implantable cardioverter-defibrillator. Heart Rhythm 2005; 2: 1094 - 1098.en_US
dc.identifier.citedreferenceBleeker GB, Schalij MJ, Molhoek SG, Verwey H, Holman ER, Boersma E, Steendijk P, Vander Wall EE, Bax JJ: Relationship between QRS duration and left ventricular dyssynchrony in patients with end-stage heart failure. J Cardiovasc Electrophysiol 2004; 15: 544 - 549.en_US
dc.identifier.citedreferenceFeldman AM, de Lissovoy G, Bristow MR, Saxon LA, De Marco T, Kass DA, Boehmer J, Singh S, Whellan DJ, Carson P, Boscoe A, Baker TM, Gunderman MR: Cost effectiveness of cardiac resynchronization therapy in the comparison of medical therapy, pacing and defibrillation in heart failure (COMPANION) trial. J Am Coll Cardiol 2005; 46: 2311 - 2321.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1540-8167.2006.00478.x.pdf
Size:
123.1KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.